South Korea remains a premier destination for uterine cancer brachytherapy, despite a clinical trend toward centralisation in Seoul. Major institutions like Seoul National University Hospital and Severance Hospital hold Joint Commission International accreditation. They use high-dose-rate iridium-192 sources to deliver essential, survival-linked radiation directly to the tumour site.
- Regional centralisation: Treatment is concentrated in major Seoul-based centres like Severance Hospital.
- HDR standardisation: High-dose-rate iridium-192 sources are the standard for cervical cancer care.
- Accredited facilities: Leading sites hold JCI and KOIHA certifications for safety and quality.
- Diagnostic requirements: Hospitals require pathology slides and imaging copies for internal lab confirmation.
- Treatment schedule: Most patients undergo 3–5 sessions over a 1–2 week period.
Bookimed Expert Insight: While national data shows fewer clinics offering this treatment, those that do are exceptionally high-volume. Severance Hospital alone manages 1.6 million outpatients annually. For Australian patients, this concentration is a benefit. It means specialists at these major Seoul centres perform the procedure daily, maintaining high technical proficiency.
Patient Consensus: Clinics in South Korea provide excellent support with professional interpreters and coordination for international files. Patients suggest asking for sedation during device insertion to manage pressure and discomfort effectively. The treatment significantly lowers recurrence risks in the vaginal vault after surgery.